Michael Benkowitz's Stock Transactions in United Therapeutics Corp

Michael Benkowitz, President and COO of United Therapeutics Corp, reported several transactions involving the company's common stock and stock options on October 27, 2025. These transactions included the exercise of stock options and subsequent sales of the resulting shares. The transactions were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to buy or sell company stock. The transactions involved significant amounts of shares, with prices ranging from $135.42 to $417.4965 per share. The filings indicate that these transactions were conducted through trusts beneficially owned by Benkowitz, with shared or sole investment and voting power.